R-5780

Phase 1Small molecule

RRise Therapeutics LLC

R-5780 is one of 18 small molecule programs targeting Solid Tumor, Adult. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor, AdultRecruiting

Solid Tumor, AdultPhase 1

Recruiting

Competition

Competitive Landscape

30 competitors in Solid Tumor, Adult

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

5 2

Avastin

Roche

Phase 1

2 3

Imfinzi

AstraZeneca

Phase 1

1 4

Jakafi

Incyte

Phase 1

1 5

Tagrisso

AstraZeneca

Phase 1

1 6

Rybrevant

Johnson & Johnson

Phase 1

1 7

Imjudo

AstraZeneca

Phase 1

1 8

Alimta

EEagle Pharmaceuticals, Inc.

Phase 1

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 10

Alimta

SShawn Eagle

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Solid Tumor, Adult

NCT06398418

Clinical

Trials by Indication[1]

Solid Tumor, Adult1 trial

A Single and Repeat Dosing and Expansion Study of the Safety, Drug Exposure and Clinical Activity of R-5780 in Combination With a PD-1 (Checkpoint Protein on Immune Cells Called T Cells) Pathway Checkpoint Inhibitor in Patients With Solid Tumors

Recruiting·RRise Therapeutics LLC·Phase 1·NCT06398418·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R-5780. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-5780 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-5780. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rise Therapeutics LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRise Therapeutics LLC

R-5780

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Solid Tumor, Adult1 trial

References

Drug Info

Quick Facts

Related News